BCL2 and neoplasm: Obatoclax mesylate (known as GX15-070) is another BCL-2 inhibitor, and the combination of obatoclax with radiation showed tumor control in nasopharyngeal carcinoma [213], prostate cancer [214], and leukemia [215].